Your browser is no longer supported. Please, upgrade your browser.
Settings
HZNP [NASD]
Horizon Therapeutics Public Limited Company
Index- P/E48.98 EPS (ttm)2.24 Insider Own0.60% Shs Outstand225.12M Perf Week1.83%
Market Cap24.71B Forward P/E19.07 EPS next Y5.75 Insider Trans-29.41% Shs Float221.29M Perf Month6.32%
Income518.20M PEG3.50 EPS next Q1.54 Inst Own91.60% Short Float1.85% Perf Quarter15.96%
Sales2.56B P/S9.66 EPS this Y-37.60% Inst Trans1.95% Short Ratio3.15 Perf Half Y22.47%
Book/sh18.10 P/B6.06 EPS next Y24.66% ROA7.40% Target Price130.27 Perf Year40.73%
Cash/sh3.61 P/C30.42 EPS next 5Y14.00% ROE13.20% 52W Range66.41 - 111.70 Perf YTD49.98%
Dividend- P/FCF47.31 EPS past 5Y48.20% ROI8.90% 52W High-1.78% Beta1.07
Dividend %- Quick Ratio2.20 Sales past 5Y23.80% Gross Margin75.90% 52W Low65.20% ATR2.48
Employees1695 Current Ratio2.60 Sales Q/Q79.90% Oper. Margin16.90% RSI (14)60.89 Volatility2.72% 2.31%
OptionableYes Debt/Eq0.63 EPS Q/Q261.90% Profit Margin20.30% Rel Volume1.37 Prev Close107.95
ShortableYes LT Debt/Eq0.63 EarningsAug 04 BMO Payout0.00% Avg Volume1.30M Price109.71
Recom1.60 SMA201.81% SMA506.14% SMA20021.46% Volume1,783,046 Change1.63%
Mar-22-21Resumed Morgan Stanley Overweight $103
Mar-12-21Initiated Wolfe Research Outperform $107
Sep-09-20Initiated JP Morgan Overweight $110
Aug-27-20Initiated Citigroup Buy $112
Jan-08-20Initiated Goldman Neutral $35
Sep-26-19Initiated BofA/Merrill Buy $34
Sep-12-19Initiated Guggenheim Buy
Aug-14-19Upgrade BMO Capital Markets Market Perform → Outperform $29 → $36
May-01-19Upgrade Citigroup Neutral → Buy $21 → $32
Mar-08-19Upgrade Morgan Stanley Equal-Weight → Overweight $32
Nov-15-18Downgrade Mizuho Buy → Neutral
Jun-27-18Downgrade Citigroup Buy → Neutral
Jan-12-18Upgrade Mizuho Neutral → Buy $12 → $18
Sep-28-17Initiated Goldman Buy $16
Jun-16-17Initiated Cantor Fitzgerald Overweight $13
May-09-17Reiterated Stifel Buy $35 → $20
May-09-17Downgrade Mizuho Buy → Neutral $22 → $10
Feb-28-17Reiterated Mizuho Buy $25 → $22
Dec-16-16Upgrade Mizuho Neutral → Buy $14 → $25
Dec-09-16Downgrade Mizuho Buy → Neutral $30 → $14
Sep-16-21 09:00AM  
Sep-07-21 08:30AM  
Sep-06-21 07:55AM  
Sep-01-21 09:10AM  
Aug-31-21 01:25PM  
Aug-23-21 04:01PM  
Aug-04-21 07:00AM  
Jul-25-21 08:45PM  
Jul-23-21 03:50AM  
Jul-22-21 12:07PM  
Jul-16-21 08:30AM  
Jul-08-21 08:00AM  
Jul-05-21 05:30AM  
Jun-30-21 08:00AM  
06:15AM  
Jun-29-21 08:00AM  
Jun-28-21 09:00AM  
Jun-21-21 12:58PM  
07:30AM  
Jun-18-21 12:30PM  
Jun-17-21 07:00AM  
Jun-08-21 04:14AM  
Jun-02-21 08:00AM  
May-27-21 08:00AM  
May-24-21 08:00AM  
May-21-21 08:00AM  
May-20-21 08:30AM  
May-13-21 11:30AM  
May-06-21 04:30PM  
08:30AM  
08:00AM  
May-05-21 12:53PM  
07:00AM  
May-04-21 01:59PM  
Apr-27-21 08:00AM  
Apr-24-21 04:44AM  
Apr-22-21 04:49PM  
Apr-21-21 07:30AM  
Apr-17-21 06:33AM  
Apr-16-21 08:30AM  
08:00AM  
Apr-12-21 03:58PM  
08:30AM  
Apr-08-21 08:00AM  
Apr-07-21 08:00AM  
Apr-05-21 08:30AM  
Mar-30-21 07:30AM  
Mar-29-21 10:05AM  
Mar-25-21 01:26PM  
08:00AM  
Mar-24-21 08:15AM  
08:00AM  
Mar-23-21 11:18AM  
Mar-22-21 04:23AM  
Mar-17-21 01:10PM  
Mar-16-21 07:35AM  
Mar-15-21 03:37PM  
01:05PM  
08:50AM  
Mar-12-21 08:45AM  
Mar-11-21 04:51PM  
03:00AM  
Mar-10-21 01:36PM  
Mar-09-21 01:16PM  
09:40AM  
Mar-08-21 09:53AM  
Feb-26-21 04:05PM  
Feb-25-21 04:05PM  
03:27PM  
12:03PM  
Feb-24-21 04:41PM  
11:01AM  
07:00AM  
Feb-22-21 09:30AM  
Feb-20-21 08:33PM  
Feb-18-21 01:08PM  
Feb-17-21 12:44PM  
Feb-10-21 01:40PM  
Feb-04-21 01:54PM  
Feb-03-21 12:53PM  
08:00AM  
Feb-02-21 07:40AM  
Feb-01-21 03:12PM  
02:57PM  
02:05PM  
09:36AM  
07:27AM  
07:00AM  
Jan-26-21 03:39PM  
01:42PM  
Jan-20-21 12:45PM  
Jan-18-21 08:46PM  
Jan-11-21 07:00AM  
Jan-08-21 02:23AM  
Jan-05-21 06:00AM  
Dec-22-20 08:00AM  
Dec-17-20 06:40AM  
Dec-15-20 04:13PM  
10:40AM  
Dec-14-20 01:58PM  
Horizon Therapeutics Public Limited Company focuses on researching, developing, and commercializing medicines that address unmet treatment needs for rare and rheumatic diseases in the United States and internationally. It operates in two segments, Orphan and Inflammation. Its medicines include KRYSTEXXA, a medicine for the treatment of uncontrolled gout; RAVICTI for use as a nitrogen-binding agent for chronic management of adult and pediatric patients; PROCYSBI for nephropathic cystinosis, a rare lysosomal storage disorder; ACTIMMUNE for chronic granulomatous disease and severe malignant osteopetrosis; RAYOS for the treatment of rheumatoid arthritis (RA), ankylosing spondylitis (AS), polymyalgia rheumatica, primary systemic amyloidosis, asthma, chronic obstructive pulmonary disease, systemic lupus erythematosus, and other conditions; BUPHENYL tablets for oral administration and BUPHENYL powder for oral, nasogastric, or gastrostomy tube administration; and QUINSAIR, a formulation of the antibiotic drug levofloxacin for the management of chronic pulmonary infections due to Pseudomonas aeruginosa in adult patients with cystic fibrosis. The company also offers PENNSAID 2% that is indicated for the treatment of pain of osteoarthritis (OA) of the knees; DUEXIS for the relief of signs and symptoms of RA and OA, and to decrease the risk of developing upper-GI ulcers; and VIMOVO for the relief of signs and symptoms of OA, RA, and AS to decrease the risk of developing gastric ulcers in patients at risk of developing NSAID-associated gastric ulcers. It has collaboration agreements with Lupus Research and HemoShear Therapeutics, LLC. The company was formerly known as Horizon Pharma Public Limited Company and changed its name to Horizon Therapeutics Public Limited Company in May 2019. Horizon Therapeutics Public Limited Company was founded in 2005 and is headquartered in Dublin, Ireland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Beeler Brian KEVP, General CounselSep 17Sale107.9128,1433,036,91162,775Sep 17 05:06 PM
Pasternak AndyEVP and Chief Business OfficerSep 09Option Exercise29.5223,250686,34046,604Sep 13 08:00 PM
Pasternak AndyEVP and Chief Business OfficerSep 09Sale107.8423,2502,507,26123,354Sep 13 08:00 PM
Walbert Timothy PChairman, President and CEOAug 27Option Exercise22.147,435164,611847,723Aug 27 05:00 PM
Beeler Brian KEVP, General CounselAug 16Option Exercise22.1465,8571,458,074165,816Aug 17 05:01 PM
Beeler Brian KEVP, General CounselAug 16Sale106.0074,8987,939,18890,918Aug 17 05:01 PM
Thompson Elizabeth H.Z.EVP, Research & DevelopmentAug 05Sale106.347,542802,02514,187Aug 06 05:03 PM
Walbert Timothy PChairman, President and CEOJul 30Sale101.7425,0002,543,489840,288Jul 30 04:28 PM
GREY MICHAEL GDirectorJul 22Option Exercise2.375,00011,8505,000Jul 23 05:00 PM
GREY MICHAEL GDirectorJul 22Sale100.045,000500,2000Jul 23 05:00 PM
MOZE BARRYEVP, Chief Admin. OfficerJul 08Sale92.5435,0763,246,01271,639Jul 09 05:00 PM
Walbert Timothy PChairman, President and CEOJun 01Sale91.8525,0002,296,204875,887Jun 03 04:41 PM
Hoelscher Paul W.EVP, CFOMay 14Sale90.01102,9259,263,847172,226May 14 06:12 PM
Kent JeffSee remarksMay 11Option Exercise22.1412,592278,78783,586May 12 05:02 PM
Daniel William FDirectorMay 10Option Exercise12.7020,000254,00020,000May 12 05:01 PM
Daniel William FDirectorMay 10Sale86.5620,0001,731,2750May 12 05:01 PM
Walbert Timothy PChairman, President and CEOApr 30Sale94.9825,0002,374,413899,838Apr 30 07:03 PM
GREY MICHAEL GDirectorApr 12Option Exercise2.3715,00035,55015,000Apr 13 06:03 PM
MOZE BARRYEVP, Chief Admin. OfficerApr 12Sale88.9665,6135,837,049105,665Apr 13 06:04 PM
GREY MICHAEL GDirectorApr 12Sale90.2815,0001,354,2000Apr 13 06:03 PM
Camardo Daniel A.EVP and President, U.S.Apr 05Option Exercise24.1818,281442,09351,181Apr 05 05:25 PM
CURTIS GEOFFREY M.EVP, Corporate Affairs, CCOApr 01Option Exercise28.4037,0001,050,710123,414Apr 02 05:13 PM
CURTIS GEOFFREY M.EVP, Corporate Affairs, CCOApr 01Sale93.5170,7396,615,09452,675Apr 02 05:13 PM
Beeler Brian KEVP, General CounselMar 31Sale90.1226,8442,419,18195,677Apr 02 05:11 PM
Camardo Daniel A.EVP and President, U.S.Mar 30Sale85.5012,9001,103,00632,900Mar 31 05:11 PM
Shannon James SamuelDirectorMar 01Option Exercise12.197,23288,1587,232Mar 03 04:46 PM
Shannon James SamuelDirectorMar 01Sale91.307,232660,2610Mar 03 04:46 PM
Walbert Timothy PChairman, President and CEOMar 01Sale91.3526,9752,464,137924,838Mar 03 04:44 PM
SANTINI GINODirectorMar 01Sale91.4712,0001,097,60023,795Mar 03 04:45 PM
DesJardin Michael A.EVP, Technical OperationsFeb 26Sale91.831,099100,92186,247Feb 26 06:12 PM
DesJardin Michael A.EVP, Technical OperationsFeb 24Sale92.4815,9441,474,44887,346Feb 26 06:12 PM
Konstantinovsky IrinaEVP, Chief Human Resources OffFeb 22Sale87.225,698496,98781,677Feb 23 06:19 PM
Karnani VikramEVP & President, InternationalFeb 22Sale87.198,358728,722104,165Feb 23 06:20 PM
DesJardin Michael A.EVP, Technical OperationsFeb 11Sale90.0010,786970,740101,200Feb 12 05:01 PM
DesJardin Michael A.EVP, Technical OperationsFeb 02Sale85.004,530385,050111,986Feb 04 05:39 PM
Walbert Timothy PChairman, President and CEOFeb 01Option Exercise0.009,087022,895Feb 03 05:24 PM
Walbert Timothy PChairman, President and CEOJan 22Sale76.4711,323865,917946,559Jan 22 08:59 PM
Konstantinovsky IrinaEVP, Chief Human Resources OffJan 22Sale76.812,226170,97986,500Jan 22 09:04 PM
Karnani VikramEVP & President, InternationalJan 22Sale76.812,731209,768111,429Jan 22 09:05 PM
Camardo Daniel A.EVP and President, U.S.Jan 21Option Exercise0.003,220046,503Jan 22 09:09 PM
Beeler Brian KEVP, General CounselJan 21Option Exercise0.004,1200123,472Jan 22 09:08 PM
McHugh Miles WSr VP & Princ. Acctg OfficerJan 21Option Exercise0.003,590035,206Jan 22 09:08 PM
DesJardin Michael A.EVP, Technical OperationsJan 21Option Exercise0.003,6780118,340Jan 22 09:06 PM
CURTIS GEOFFREY M.EVP, Corporate Affairs, CCOJan 21Option Exercise0.003,760087,205Jan 22 09:07 PM
Karnani VikramEVP & President, InternationalJan 21Option Exercise0.004,9040116,333Jan 22 09:05 PM
Konstantinovsky IrinaEVP, Chief Human Resources OffJan 21Option Exercise0.003,999090,498Jan 22 09:04 PM
MOZE BARRYEVP, Chief Admin. OfficerJan 21Option Exercise0.005,8190172,762Jan 22 09:03 PM
Kent JeffSee remarksJan 21Option Exercise0.003,045071,468Jan 22 09:02 PM
Hoelscher Paul W.EVP, CFOJan 21Option Exercise0.005,55606,605Jan 22 09:01 PM
Walbert Timothy PChairman, President and CEOJan 21Option Exercise0.002,575014,563Jan 22 08:59 PM
Walbert Timothy PChairman, President and CEOJan 21Option Exercise0.0020,3300966,889Jan 22 08:59 PM
SHERMAN JEFFREY WEVP and Chief Medical OfficerJan 21Option Exercise0.005,353081,361Jan 22 09:00 PM
Walbert Timothy PChairman, President and CEOJan 15Sale77.89211,20416,449,893946,559Jan 15 05:43 PM
DesJardin Michael A.EVP, Technical OperationsJan 06Option Exercise16.3527,106443,296141,768Jan 08 05:32 PM
Konstantinovsky IrinaEVP, Chief Human Resources OffJan 06Sale74.7626,8442,006,85486,499Jan 08 05:33 PM
Karnani VikramEVP & President, InternationalJan 06Sale75.0030,0312,252,325111,429Jan 08 05:31 PM
DesJardin Michael A.EVP, Technical OperationsJan 06Sale75.0027,1062,032,950114,662Jan 08 05:32 PM
McHugh Miles WSr VP & Princ. Acctg OfficerDec 14Sale80.001,856148,48019,741Dec 15 05:00 PM
DesJardin Michael A.EVP, Technical OperationsDec 10Sale69.645,909411,50363,392Dec 11 04:41 PM
SHERMAN JEFFREY WEVP and Chief Medical OfficerDec 08Sale71.1540,7642,900,354174,955Dec 09 05:05 PM
SHERMAN JEFFREY WEVP and Chief Medical OfficerDec 07Sale70.9463,0784,474,860215,719Dec 09 05:05 PM
McHugh Miles WSr VP & Princ. Acctg OfficerNov 12Sale75.4812,124915,12021,597Nov 13 07:27 PM
Camardo Daniel A.EVP and President, U.S.Nov 06Sale76.763,500268,66330,829Nov 06 06:00 PM
Kent JeffSee remarksNov 05Sale78.9447,9443,784,66351,049Nov 06 06:00 PM
MOZE BARRYEVP, Chief Admin. OfficerNov 05Sale78.9377,5006,117,259100,709Nov 06 06:00 PM
SHERMAN JEFFREY WEVP and Chief Medical OfficerOct 21Option Exercise7.6113,00098,93028,015Oct 21 05:06 PM